Nivolumab
| Nivolumab | |
|---|---|
| Term | Nivolumab |
| Short definition | Nitrosourea - (pronounced) (ny-TROH-soh-YOO-ree-uh) A cancer drug that can cross the blood-brain barrier. Carmustine and lomustine are nitrosoureas |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Nivolumab - (pronounced) (nih-VOL-yoo-mab) drug that binds to the protein PD-1 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that express the protein PD-L1 or have certain mutations (changes) in genes involved in DNA repair. Nivolumab is used alone or with other medicines to treat certain types of cancer of the esophagus, gastroesophageal junction, stomach cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), melanoma, hepatocellular carcinoma (a type of liver cancer), squamous cell carcinoma head and neck, classic Hodgkin's lymphoma, urothelial carcinoma (a type of bladder or urinary tract cancer) and malignant pleural mesothelioma. It is also being studied in the treatment of other types of cancer. Nivolumab can block PD-1 and help the immune system kill cancer cells. It's a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Opdivo
External links
- Medical encyclopedia article on Nivolumab
- Wikipedia's article - Nivolumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski